facebook pixel code
RethinkALZ and RefocusALZ Clinical Research Studies
open icon close icon
Complete the Pre-Screener
image of colored blocks

RESEARCH TO HELP
ADVANCE THE TREATMENT
OF ALZHEIMER’S

The rethinkALZ and refocusALZ clinical research studies are currently testing the study drug, simufilam, to see if it is safe and effective in treating and slowing down the progression of mild-to-moderate Alzheimer's disease.

Complete the Pre-Screener

Study Participation

The rethinkALZ and refocusALZ clinical research studies are enrolling patients!

To be considered for the rethinkALZ study or refocusALZ study, patients must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Other criteria will apply.

Study Participation

We are looking for participants for both the rethinkALZ and refocusALZ studies. Participation will last either 52 or 76 weeks. If you enroll into one of these studies, you will receive either the study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There will be no cost for the study drug or any study-related procedures. No hospitalization will be required. You may be compensated for your time and travel for each clinical study appointment.

Complete the Pre-Screener

What are clinical research studies?

Clinical research studies, also known as clinical trials, are conducted by doctors and researchers to see if new medications or treatments are safe and effective before being approved for use by the public. For many people, taking part in a clinical trial is important because their participation helps increase the understanding of various diseases and how to treat them. Some other benefits to participation are:

Refer A Friend

Do you know a family member or loved one who is diagnosed with Alzheimer’s disease? They may be eligible to participate in either the rethinkALZ or refocusALZ clinical research studies. Consider sharing information with them about how they can learn more.

Share this Study
Complete the Pre-Screener